A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
Status:
Completed
Trial end date:
2020-11-02
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of tislelizumab assessed by
Independent Review Committee (IRC) in participants with relapsed or refractory classical
Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano
Classification